Off-Label Uses Of Drugs Should Be Approved For Very Ill Patients, Opinion Piece States

Main Category: Cancer / Oncology
Also Included In: Primary Care / General Practice;  Public Health;  Regulatory Affairs / Drug Approvals
Article Date: 06 May 2009 - 4:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated


FDA and Congress "should protect physicians' and patients' right" to use FDA-approved drugs for off-label uses "and for the first time allow drugmakers to promote off-label uses that prove beneficial," Richard Epstein, a law professor at the University of Chicago and a senior fellow at the Hoover Institution, writes in a Wall Street Journal opinion piece. He continues, "Right now these drugs provide immense lifesaving opportunities for many sick patients, particularly those threatened by cancer."

Epstein writes, "Cancer patients are often in desperate straits" and "when existing treatments fail, patients and physicians alike can rationally conclude that they lose nothing by rolling the dice." He continues, "Clinical trials sometimes give way to educated guesses that a drug approved for one kind of tumor might treat a second," adding, "In many instances the result is failure." However, "when early results from clinical trials suggest favorable results on which the FDA is unwilling to act, off-label use begins in earnest," Epstein writes.

Epstein writes, "Any reliable information about what drugs work has the potential to save lives -- but the FDA's slow and ponderous system can't respond in real time to new data." He adds, "As matters now stand, no off-label use is possible for any drug that has not been certified for some particular on-label use," which "reduces the number of drugs available on the market for off-label experimentation."

Epstein continues, "No one thinks that unapproved cancer drugs should be freely available to patients in the over-the-counter market." However, making drugs that pass Phase I clinical trials available for general distribution is an option. He concludes, "This may sound radical. But when lives are at stake, we should consider drastic measures" (Epstein, Wall Street Journal, 5/2).

Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation.

© 2009 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

Article adapted by Medical News Today from original press release.
Visit our cancer / oncology section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Kaiser. "Off-Label Uses Of Drugs Should Be Approved For Very Ill Patients, Opinion Piece States." Medical News Today. MediLexicon, Intl., 6 May. 2009. Web.
16 Feb. 2012. <http://www.medicalnewstoday.com/releases/149011.php>

APA
Kaiser. (2009, May 6). "Off-Label Uses Of Drugs Should Be Approved For Very Ill Patients, Opinion Piece States." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/149011.php.

Please note: If no author information is provided, the source is cited instead.


Cancer / Oncology

What is Cancer?

Cancer is a class of diseases characterized by out-of-control cell growth. There are over 100 different types of cancer, and each is classified by the type of cell that is initially affected. Read more...

Most Popular Articles



Follow Our Cancer News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Cancer / Oncology Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »